Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021




Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to present at the SNN Network Canada Virtual Event taking place on December 7-9, 2021.

Mr. Seto is scheduled to present on Wednesday, December 8, 2021, at 9:00 A.M. Eastern Time. The event will be broadcast live and can be accessed and replayed here.

Mr. Seto will also host one-on-one meetings with qualified investors throughout the conference. Registration is complimentary for qualified investors. For more information or to register for the event, please visit canada.snn.network.

About SNN Network Canada Virtual Event

SNN Network and Small Cap Discoveries, the leading Canadian MicroCap newsletter, have teamed up to highlight our neighbors to the North: Canada. Between SNN’s audience and Small Cap Discoveries’ newsletter following, we have joined forces to provide a platform for investors to learn about the highest quality public micro cap companies listed on Canadian exchanges, as well as hear from fund managers, newsletter writers and financial influencers with experience and expertise investing in these Canadian assets.

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (“RRT”) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Contact:

Mr. Chris Seto Mr. Ali Mahdavi David Waldman/Natalya Rudman
CEO Capital Markets & Investor Relations US Investor Relations
Spectral Medical Inc. Spinnaker Capital Markets Inc. Crescendo Communications, LLC
416-626-3233 ext. 2004 416-962-3300 212-671-1020
cseto@spectraldx.com am@spinnakercmi.com edt@crescendo-ir.com